Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology COVID registry.

Fecha de publicación: 01/09/2023 Fecha Ahead of Print: 01/09/2023

Autores de IIS La Fe

Ana Ventura Galiano

Autor

Participantes ajenos a IIS La Fe

Lopez-Oliva, Maria O
Perez-Flores, Isabel
Molina, Maria
Jose Aladren, Maria
Trujillo, Hernando
Redondo-Pachon, Dolores
Lopez, Veronica
Facundo, Carme
Villanego, Florentino
Rodriguez, Marisa
Carmen Ruiz, Maria
Anton, Paula
Rivas-Oural, Alba
Cabello, Sheila
Portoles, Jose
de la Vara, Lourdes
Tabernero, Guadalupe
Valero, Rosalia
Galeano, Cristina
Moral, Esperanza
Coca, Armando
Angel Munoz, Miguel
Hernandez-Gallego, Roman
Shabaka, Amir
Ledesma, Gabriel
Bouarich, Hanane
Angeles Rodriguez, Maria
Perez Tamajon, Lourdes
Cruzado, Leonidas
Emilio Sanchez, Jose
Jimenez, Carlos

Abstract

INTRODUCTION: SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the management of the infection in the absence of targeted antiviral treatment. This has been modified according to the patient`s clinical situation and its effect on renal function or anti-HLA antibodies in the medium term has not been evaluated. OBJECTIVES: Evaluate the management of immunosuppressive therapy made during SARS-CoV2 infection, as well as renal function and anti-HLA antibodies in kidney transplant patients 6 months after COVID19 diagnosis. MATERIAL AND METHODS: Retrospective, national multicentre, retrospective study (30 centres) of kidney transplant recipients with COVID19 from 01/02/20 to 31/12/20. Clinical variables were collected from medical records and included in an anonymised database. SPSS statistical software was used for data analysis. RESULTS: renal transplant recipients with COVID19 were included (62.6% male), with a mean age of 57.5 years. The predominant immunosuppressive treatment prior to COVID19 was triple therapy with prednisone, tacrolimus and mycophenolic acid (54.6%) followed by m-TOR inhibitor regimens (18.6%). After diagnosis of infection, mycophenolic acid was discontinued in 73.8% of patients, m-TOR inhibitor in 41.4%, tacrolimus in 10.5% and cyclosporin A in 10%. In turn, 26.9% received dexamethasone and 50.9% were started on or had their baseline prednisone dose increased. Mean creatinine before diagnosis of COVID19, at diagnosis and at 6 months was: 1.7?±?0.8, 2.1?±?1.2 and 1.8?±?1?mg/dl respectively (p?<?0.001). 56.9% of the patients (N?=?350) were monitored for anti-HLA antibodies. 94% (N?=?329) had no anti-HLA changes, while 6% (N?=?21) had positive anti-HLA antibodies. Among the patients with donor-specific antibodies post-COVID19 (N?=?9), 7 patients (3.1%) had one immunosuppressant discontinued (5 patients had mycophenolic acid and 2 had tacrolimus), 1 patient had both immunosuppressants discontinued (3.4%) and 1 patient had no change in immunosuppression (1.1%), these differences were not significant. CONCLUSIONS: The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis.